New formulation modelling successes using ex vivo tissue

9 Oct 2018

One study uses the company's proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails.

MedPharm’s unique expertise to model the behaviour of pharmaceutical formulations using ex vivo human tissue is being successfully applied across of growing range of applications. Two examples published in the Journal of Dermatological Treatment and presented at the 3rd German Pharm-Tox Summit demonstrate this - one using human nails, the other human larynx tissue.

New formulation modelling successes using ex vivo tissue
MedPharm claims an increasing number of performance tests can be done using their ex vivo human tissue banks.

This first study, published in the Journal of Dermatology Treatment entitled “In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails” describes the use of MedPharm’s proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails for the treatment of onychomycosis (T. rubrum) MedPharm’s scientists were able to show that the application of nail polish to the nail had no impact on the ability of the drug to penetrate or kill the fungal infection.

The second was described In a poster at the 3rd German Pharm-Tox Summit this year entitled “Determination of the permeation and penetration of Flurbiprofen from a locally acting sore throat lozenge and spray into human pharynx tissue” MedPharm scientists compared the penetration of Flurbiprofen into ex vivo human larynx tissue when delivered by spray or lozenge. In both cases it was demonstrated that there was rapid and deep drug penetration. This provides strong support that both treatments can provide quick acting relief.

Dr Rob Turner, MedPharm’s Senior Director of Innovation, commented: “MedPharm has 20 years of experience in modelling the behaviour of formulated drugs using skin and other ex vivo human tissue in the laboratory. These examples are just two ways in which our models can be employed to expand the clinical applicability of a product. MedPharm is continuously investing in research to increase the sophistication of its models.”

“We routinely use fresh healthy ex vivo human skin to monitor the biological activity of many drug candidates as well as their penetration and permeation,” added Dr Jon Lenn, MedPharm’s Chief Technology Officer. “We can maintain the viability of the skin up to 10 days in the laboratory which greatly increases the options we have for monitoring and optimising both drug and drug product performance.”

Read More

Related news

Spanish CDMO working ahead of EU serialisation deadline

Spanish CDMO working ahead of EU serialisation deadline

6 Dec 2018

Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

Read more 
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

5 Dec 2018

The financing will power the global commercial launch of the company's Fluidity One system.

Read more 
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

4 Dec 2018

The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

Read more 
NIH to evaluate effectiveness of male contraceptive skin gel

NIH to evaluate effectiveness of male contraceptive skin gel

28 Nov 2018

The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

Read more 
QPS expands US-based Phase I clinical trial capabilities

QPS expands US-based Phase I clinical trial capabilities

27 Nov 2018

Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

Read more 
Grant winners to investigate continuous manufacturing for gene therapies

Grant winners to investigate continuous manufacturing for gene therapies

26 Nov 2018

Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more 
Plasticell receives EU funding to advance neurodegenerative disease research

Plasticell receives EU funding to advance neurodegenerative disease research

1 Nov 2018

Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.

Read more 
Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

30 Oct 2018

Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.

Read more 
SIRIO Pharma opens multimillion gummy production plant

SIRIO Pharma opens multimillion gummy production plant

18 Oct 2018

The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

Read more